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Abstract
Aim: The aim of this paper is to describe the time spent to activate oncological non-profit clinical trials promoted in Italy by
the National Cancer Institute of Naples, following the implementation of recent European laws.
Methodology: Data about the process of activation of 5 non-profit multicentre clinical trials were prospectively collected
through a web-based system. The impact of European guidelines was assessed by comparing the efficiency of the process
between applications started before and after the decree introducing in Italy the Clinical Trial Application form (MD-CTA).
Outcomes of the descriptive analyses were the time to EC opinion, the time to administrative agreement signature after a
positive EC opinion, and the cumulative percentage of submissions that came to closure (either positive or negative) within
four subsequent time cohorts.
Principal Findings: From March 2007 to October 2009, 202 applications were submitted to 107 centres. Forty-four (59%)
applications of those submitted before were successful, compared to 71 (55%) of those submitted after MD-CTA. Most of
the failures were due to missing EC response (27% and 22%) or administrative reasons (10% and 16%, before and after,
respectively); very few (4% and 7%) were due to EC refusal. The impact of the MD-CTA on time to EC opinion looked positive
(median 4.1 vs 2.4 months, before and after, respectively) but a subgroup analysis revealed that the impact was limited to a
comparison biased by the selection of EC. After a positive EC opinion, there was no difference before and after MD-CTA in
the time to administrative agreement signature (median 3.6 and 3.8 months, respectively). A trend to shortening time to
closure of the whole submission process over the time was evident, with 58% of the applications coming to closure within 6
months from submission in the most recent cohort.
Conclusions: In our experience there is reassuring evidence of a trend toward shortening the time spent to activate non-
profit clinical trials in Italy, but the whole process still remains inefficient. Efforts should be made to improve the process,
also focusing on administrative procedures.
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Introduction
Clinical research is regulated in Europe by the 2001/20/EC
Directive,which shouldharmonizenationallawsand administrative
provisions regarding clinical trials conduction [1]. In particular, the
directive establishes at 60 days the maximum time to obtain the
opinion of ethical committees (EC), including 30 days for issuing
the so-called ‘‘single’’ opinion by the EC of the coordinating centre
and 30 days for the acceptance or refusal of the ‘‘single’’ opinion by
the EC of clinical centres willing to participate. The directive does
not make any substantial difference between commercial (also
defined ‘‘profit’’) and academic independent (‘‘non-profit’’) clinical
trials. In Italy, the European directive has been implemented with
the Legislative Decree 211/2003; thereafter, further guidance has
been provided with the implementation of Ministerial Decree 17
December 2004, that innovatively defined rules for non-profit
clinical research [2,3]. According to the European directive, the
procedure for the activation of multicentre clinical trials foresees
subsequent phases: first, the submission of the clinical trial appli-
cation to EC of the coordinating and the participating centres;
second, the issue of the ‘‘single’’ opinion by the EC of the
coordinating centre and, if this opinionis positive, the acceptance or
the refusal by EC of each participating centre; third, in case of
acceptance, the signature of administrative agreement between the
coordinating and each participating centre (figure 1).
The 7
th Bulletin of the National Monitoring Centre for Clinical
Trials, reporting data on clinical trials of drugs in Italy in the years
2004–2007, showed that only 27.3% of peripheral EC issued their
opinion within the time frame established by law, and that mean
time of issuing EC opinion was 4.3 months [4]. A survey on the
PLoS ONE | www.plosone.org 1 July 2010 | Volume 5 | Issue 7 | e11864work of 134 Italian EC on a single trial reported a large variability
of the procedures for clinical trial application, both for the number
and the format of the documents. In fact, the number of required
documents ranged from 6 to 21; at least one personalized
document was required in most cases (57%) and the number of
hardcopies ranged from 6 to 249 (5). Furthermore, 26.9% of EC
asked for submission by e-mail or CD-ROM (number of copies
ranging from 1 to 15) in addition to the paper version. In that
survey, the median time from submission to final opinion was 72
days, longer than that mandated by the European Directive [5].
The scenario could have changed in Europe thanks to the
publication of the detailed guidance on the modalities of clinical
trial authorisation request to competent authorities [6], on the
format of the application and the documentation to be submitted
for EC opinion [7], and on investigational medicinal products and
other medicinal products [8]. These guidelines were received in
Italy in December 2007, with the Ministerial Decree on clinical
trial application (MD-CTA) entering into force on July 4
th, 2008
[9]. The MD-CTA defines all the operative procedures and the
documents required for the authorisation of a clinical trial; it also
establishes the maximum number of paper copies to submit to EC
and introduces the CTA form, with the aim of uniquely identifying
the clinical trial, the organisations and the key individuals
responsible for the conduct of the trial.
The aim of the present study is to assess the impact of the MD-
CTA on time to EC opinion and to administrative signature, and
to describe the efficiency over time of the whole process of
activation of non-profit multicentre clinical trials promoted by the
Clinical Trials Unit of the NCI of Naples.
Methods
Data on the process of activation of non-profit multicentre
clinical trials coordinated by the Clinical Trials Unit of the NCI of
Naples were prospectively collected through a web-based system
(http://www.usc-intnapoli.net). Three time milestones were con-
sidered for each application: the date of submission to EC, the date
of EC opinion, and the date of signature of administrative
agreement.
The impact of MD-CTA was assessed by comparing the
efficiency of the process between applications started before (i.e.
between March 1
st, 2007 and July 3
rd, 2008) and after (i.e.
between July 4
th, 2008 and October 31
st, 2009) it entered into
force in Italy. Data for the analysis were frozen at January 31
st,
2010. Time to EC opinion was calculated as the interval from
submission to the date of EC opinion either negative or positive,
censoring at January 31
st, 2010, cases with no EC opinion. Time
to administrative agreement signature after a positive EC opinion
was calculated as the interval from the date of EC opinion to the
date of signature, censoring at January 31
st, 2010, cases with no
signature. Both of these outcomes were described with Kaplan-
Meier curves. The efficiency of the whole process of activation,
affected by both time to EC opinion and time to administrative
signature, was described for four consecutive cohorts of submis-
sions, based on 8-month periods of time. A submission was
considered closed either in case of signature of the administrative
agreement or in case of negative EC opinion.
Due to the descriptive nature of the study, no formal statistical
analysis was performed.
Results
From March 1
st, 2007 to October 31
st, 2009, the Clinical Trials
Unit of NCI of Naples promoted five multicentre clinical trials
(Table 1). A total of 202 applications were submitted to the EC of
107 Italian centres, with a median of 2 (range 1–5) applications for
each centre. In particular, 74 applications were made before and
128 after MD-CTA. Twenty-two EC received applications both
Figure 1. Flow of clinical trials application according to 2001/20/EC Directive.
doi:10.1371/journal.pone.0011864.g001
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or only after (51) MD-CTA. Thirty-nine (36%) centres were
located in northern Italy, 22 (21%) in central Italy and 46 (43%) in
southern Italy or islands. In all cases, the application was
prompted by the Investigator’s declaration of the will to participate
in the proposed clinical trials.
Forty-four (59%) applications submitted before MD-CTA were
successful, compared to 71 (55%) of those submitted after. Failures
in this process were similarly distributed before and after MD-
CTA. Most of the failures were due to missing EC response (27%
and 22% before and after, respectively) or administrative reasons
following a positive EC opinion (10% and 16%, respectively); very
few failures (4% and 7%, respectively) were due to EC negative
opinion (figure 2).
Overall, median time to EC opinion was 2.9 months and only
37% of the opinions were issued within the 2-month time window
indicated by law. The impact of MD-CTA on time to EC opinion
is displayed in figure 3; the top graph, including all submissions,
suggests that time to EC opinion was shorter after (median 2.4
months) than before (median 4.1 months) MD-CTA. However,
bottom graphs show that there was no difference in time to EC
opinion if the analysis is limited to EC that were involved both
before and after MD-CTA (on different clinical trials), while a
large difference was evident in the comparison including EC that
were involved only before or only after MD-CTA.
After a positive EC opinion (figure 4), there was no difference
before and after MD-CTA in the time required to sign the
administrative agreements (median 3.6 and 3.8 months, respec-
tively).
A trend toward shortening time to closure of the whole
submission process over time is evident in the graphical description
reported in figure 5. Indeed, the rate of submissions that reached
Table 1. Characteristics of the trials.
Application to EC
Trial
EudraCT
number
Type of
Cancer
Planned
patients
Before MD-CTA entered
into force (No. 74)
After MD-CTA entered
into force (No. 128)
TORCH 2005-005968-90 NSCLC* 900 13 1
CAPPA – 2 2005-005631-97 NSCLC* 360 23 16
STAD – 1 2006-003995-36 SCLC** 160 38 4
MITO – 7 2008-001754-40 Ovarian 400 - 53
MITO – 8 2008-001755-22 Ovarian 250 - 54
*NSCLC: Non-small-cell-lung-cancer.
**SCLC: Small-cell-lung-cancer.
doi:10.1371/journal.pone.0011864.t001
Figure 2. Data flow of application outcome before and after MD-CTA entered into force in Italy.
doi:10.1371/journal.pone.0011864.g002
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opinion) within 6 months from the date of submission has
increased from 23% in the oldest cohort to 58% in the most recent
one; however, in the latter cohort, only 15% of the submission
came to closure within 3 months.
Discussion
Our study shows that there is an encouraging trend toward
shortening the time spent for activation of non-profit studies in
oncology in Italy, in the experience of a single promoting centre.
Such shortening does not seem related to changes in the time
required for administrative agreement signature that did not vary
before and after MD-CTA. Rather, it seems that it may derive
from a higher efficiency of EC. However, we cannot draw
definitive conclusions on the role played by the MD-CTA because
we see shorter time to EC opinion after MD-CTA only in the
more biased comparison that include EC involved only before or
only after MD-CTA; therefore, it is reasonable that the observed
difference is due to a selection bias of EC, rather than to the effect
of MD-CTA.
However, the whole process remains inefficient, with about a
40% failure rate, quite high considering that all submissions in our
case were prompted by the declared interest of investigators at
participating centres. In addition, it is regrettable that, in the most
recent and best performing cohort of submissions, only 15% of
procedures came to closure within 3 months. Such lack of
efficiency is extremely burdensome for promoters, particularly the
non-profit ones always working with limited economic resources.
Application failures are primarily due to lack of EC response
and administrative reasons, and only rarely to a negative opinion
and a refusal by EC. We believe that the high number of EC plays
a role in the lack of efficiency. According to the last version of
Bulletin of the National Monitoring Centre for Clinical Trials, 269
EC are active in Italy [10]. It is reasonable that, within such a high
number of EC, many lack minimum structural requirements to
work efficiently; these committees actually prevent the possibility
of clinical investigators and their patients to participate in clinical
trials that might in some cases offer positive chances of treatment.
The administrative approval process seems completely unaf-
fected by MD-CTA, in our experience, although the EU directive
was intended to harmonize administrative procedures as well as
the work of EC. However, the directive is not mandatory
regarding time allowed for administrative approval, further,
administrative authorities might lack sensitivity to the value of
clinical trials and their management. This is clearly supported by
Figure 3. Time to EC opinion. Top graph includes all submissions; bottom left graph includes only data of EC involved both before and after MD-
CTA; bottom right graph includes only data of EC involved only before or only after MD-CTA. Vertical lines represent censored applications.
doi:10.1371/journal.pone.0011864.g003
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doi:10.1371/journal.pone.0011864.g004
Figure 5. Cumulative percentage of applications, divided in four time cohorts, coming to closure over the time.
doi:10.1371/journal.pone.0011864.g005
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positive EC opinion in 27 of 142 cases. This is hard to accept, even
if this figure might be overestimated because some of the most
recent applications could become successful after the limiting date
chosen for the analysis.
Our data are consistent with literature suggesting that steps and
time required to develop and activate multicentre clinical trials are
too extensive and the development time is overly long and highly
variable [11,12]. In particular, prolonged delays in obtaining
regulatory approvals to initiate clinical trials is reported in many
countries, where obtaining approval can take as long as 6 to 9
months [13], a time so long to be unethical [14].
Therefore, major efforts should be made to reduce and
standardize procedures concerning the approval of clinical trials,
also focusing on administrative procedures, because time to trial
activation is critical for clinical research.
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